Osmetech acquired the Opti product line from Roche Diagnostics. Opti is the portable analysis technology for bloodgas and electrolytes measurement. This highly successful analyser has also taken the veterinary world by storm. IDEXX Laboratories Inc (IDXX) have entered into a ten year OEM agreement to provide the customised OPTI analysers to the veterinary field under the brand VetStat.

In September 2004 the company acquired the "OPTIgene" (Genedrive) product from MS this technology will enable OMH a strong entry point into the fastest growing market segment of DNA based diagnostics. A market that is growing at an annual rate of 20% and is currently worth $ 22 bln !

In the latest acquisition 1/7/05 Osmetech acquired Clinical Micro Sensors from Motorola PLC, OMH plans to utilise the eSensor technology coupled with OPTIgene to address the majority of existing and new tests in the genetic diagnostics market. 'CMS's diagnostic tests for cystic fibrosis and CYP450 are closest to commercial launch and OMH believes that these products have significant market potential.

Scroll & Click for Websites & Other LinksRT Mag Wall Street Reporter Interviews JW

Up Coming Events in 2006

CMS CYP450 product Launch!!!!!............................................. 2006

IDEXX critical care platform Launch!!!!!....................................2006/7....much more to follow

Click Here to Track Osmetech's Progress in the "Stocks That Could Double in 2006" Competition

AGM Date WEDNESDAY 3RD MAY

Looks like that's the order from the past few days...

Time Price Quantity Type Bid Offer Buy/Sell Total Buy Total Sell Total Unknown
04/04/06 13:07 23.0 957,000 VW 22.5 23.0 Buy 1,111,218 578,526 13,000

Another volume weighted trade BUY 836,417 @ 23.50p - the top end of the spread for the past week. Small time sellers seem to be filling these institutional purchases.

Hoare Govett to release a brokers note later today or next week.

Bangersman / dichpig / others

Got my copy of OMH accounts, they want me to vote on:

1 To Re-elect: J N G White director. ?
2 To Re-elect: G B Kuenster director. ?
3 To autherise directors to allot shares of up to 43,935 ?

Plus several other things what do you all think on these yes /no ?

The changes to the LTIP will be getting a 'No' from me, dangle the carrot slightly further away.

The rest of the resolutions are pretty obvious or just formality.

Next buy signal on OMH 3 box is only a tick away.

Looking good...

OMH (Osmetech) Tipped as a BUY in todays Sunday Telegraph
Sunday Telegraph (UK) - Apr. 23, 2006

KEEP an eye on Osmetech, the healthcare diagnostics group (24p).

Under the stewardship of James White, the company has developed into a business with sales, mainly thanks to a handful of acquisitions.

In results published last month, Osmetech revealed that sales for the eight months to December 31 were up by 78 per cent on the corresponding period.

Its investment in its critical care business is also paying off, with sales up by 64 per cent to $14.8m ( pounds 8.3m).

Since then it has announced the launch of its eSensor cystic fibrosis carrier detection (CFCD) test and its eSensor 4800 DNA detection instrument.

The eSensor system can be used to perform molecular tests that require the simultaneous analysis of multiple genetic information. Product shipments are expected to begin on schedule during the first half of this year, the company said.

We believe the shares look like good value. Buy.

The fuse has been lit...again.

More institutional buying taking place today.

Time Price Quantity Type Bid Offer Buy/Sell Total Buy Total Sell Total Unknown
25/04/06 15:11 25.0 1,000,000 O 24.5 25.0 Buy 2,024,664 238,725 5,020
25/04/06 15:18 25.0 825,000 O 24.5 25.0 Buy 2,901,664 238,725 5,020
25/04/06 10:16 25.0 500,000 O 24.5 25.25 Buy 570,031 92,432 0
25/04/06 10:24 25.0 250,000 O 24.5 25.25 Buy 970,031 95,338 0
19/04/06 16:00 24.0 250,000 O 22.5 24.5 Buy 339,399 223,584 15,000
19/04/06 19:02 24.0 250,000 B 22.5 24.5 ? 0 0 0
25/04/06 10:21 25.0 100,000 O 24.5 25.25 Buy 720,031 95,338 0
24/04/06 16:56 25.0 100,000 O 23.0 26.0 Buy 422,530 171,071 305,000

Link

copycat

(lol)
There's an ascending triangle pattern occurring. So when 25p breaks the move to 30p should be even more rapid.
Ascending triangles
free stock charts from ADVFN.COM

I am a holder in OMH and have been for many years, I hope they do break upwards, but your chart shows 3 ascending triangles the first 2 break down !

Lets hope it's third time lucky then. Looking at yesterdays trades someone feels confident!

So it was UBS AG that were buying. Looking good!Osmetech PLC
26 April 2006

Osmetech plc ('Osmetech' or 'the Company')



The Company was notified, on 25th April 2006, that UBS AG has an interest in
8,825,000 ordinary shares of 0.1 pence each in Osmetech.

The total holding represents approximately 6.70 per cent of the Company's issued
ordinary share capital.

IDEXX Laboratories First Quarter 2006 Earnings Conference Call
Friday, April 28, 2006 - 9:00 AM ET

(Might give an update on VetStat sales and progress of CC platform)

AGM Statement

RNS Number:3112C
Osmetech PLC
03 May 2006





3 May 2006



Osmetech plc - AGM Statement

Osmetech plc, the international healthcare diagnostics group will provide the
following update during its Annual General Meeting at 11:00am today:

Critical Care Division

Our Critical Care business continues to build on the sales growth achieved in
2005 and as expected, demand in the current year for the Division's OPTI range
of blood gas analysis products has remained strong in both the human and
veterinary markets.

For the remainder of 2006 we expect the healthy levels of demand in the Critical
Care Division to continue and therefore be another year of growth for this
division.

Molecular Diagnostics Division

Osmetech continues to make significant progress and remains on schedule with its
new product launches. As planned, in March we launched our FDA approved eSensor
Cystic Fibrosis Carrier Detection test and eSensor 4800 DNA Detection instrument
and later this month we will launch our OPTI TUBE product for use in the Roche
LightCycler as a cost-effective and safe alternative to the Roche glass
capillaries. Our OPTI GENE instrument and proprietary consumable system for the
rapid detection of DNA and RNA targets will be available for sale in June,
although the product will be fully launched with thrombophilia assays at the
American Association of Clinical Chemists (AACC) Conference in Chicago in July.

We have been delighted with the initial stages of product commercialisation in
this fast growing market sector. We plan to replicate the successful Critical
Care business model of selling instruments and proprietary tests primarily to
small and medium sized hospitals across the globe through our well established
distribution networks.

The installation of instruments will provide the basis of future revenues by
introducing a wider range of tests, developed both by Osmetech and third
parties. In addition, our instruments have significant potential in other
markets, such as veterinary, environmental and forensics, which we would look to
exploit through strategic partnerships.

Outlook

The Board remains confident that 2006 will be a strong year for Osmetech.

Our Critical Care Division is on track to achieve another profitable performance
and will continue to provide a strong base and proven infrastructure for the
Group overall as we introduce products in the molecular diagnostics market.

We fully expect to be able to demonstrate the value of our strong position and
the considerable opportunities that exist in the exciting molecular diagnostics
market as we enter the important commercialisation phase.

Ends

For further information:

Osmetech plc +44 (0)207 849 6027
James White, Chief Executive Officer
David Sandilands, Chief Financial Officer

madano partnership +44 (0)207 593 4000

Matthew Moth

Mark Way

The installation of instruments will provide the basis of future revenues by
introducing a wider range of tests, developed both by Osmetech and third
parties. In addition, our instruments have significant potential in other
markets, such as veterinary, environmental and forensics, which we would look to
exploit through strategic partnerships.

We fully expect to be able to demonstrate the value of our strong position and
the considerable opportunities that exist in the exciting molecular diagnostics
market as we enter the important commercialisation phase.

Another large holder has shown their hand. 3%+ holders and directors now control c63% of the issued shares of the company.

Osmetech PLC
05 May 2006

Osmetech plc ('Osmetech' or 'the Company')



The Company has been notified that following the acquisition of 1,100,000
ordinary shares, Universities Superannuation Scheme Limited now has an interest
in 4,780,000 Osmetech shares. The shares are registered under Chase Nominees Ltd
(USS).

The total holding represents approximately 3.627 per cent of the Company's
issued ordinary share capital.